Video

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Based on level 1 evidence, there is good data to support the use of pertuzumab (Perjeta) plus trastuzumab (Herceptin) with chemotherapy in the first line setting. This is then followed by T-DM1 in the second line, states Pegram.

This has set the standard of care for the HER2-postive metastatic breast cancer patient population, explains Pegram.

Related Videos
 Rupesh Rajesh Kotecha, MD
David A. Braun, MD, PhD
Francine Foss, MD
Daniel E. Haggstrom, MD
Ami Umesh Badami, MD
Kenneth Shain, MD, PhD
Piotr Rutkowski, MD
Manali Kamdar, MD, of University of Colorado Anschutz School of Medicine
Janaki Neela Sharma, MD, assistant professor, clinical medicine, Genitourinary Medical Oncology, University of Miami Health Systems
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems